Drugs / bepranemab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04658199 | Nov 2020 → Dec 2027 expected | progressive supranuclear palsy | UCB Biopharma SRL | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04185415 | Dec 2019 → Nov 2021 | progressive supranuclear palsy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT03605082 | Jul 2018 → Mar 2019 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT03464227 | Feb → Dec 2018 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04867616 | Jun 2021 → May 2024 | Alzheimer disease | UCB Biopharma SRL | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bepranemab | “UCB0107 (bepranemab)” NCT04658199 ↗ |
| Known as | UCB0107 | “A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)” NCT04867616 ↗ |
| Action | Inhibit | “Microtubule-associated protein tau inhibitor” CHEMBL4594612 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594612 ↗ |
| Route | Intravenous | “Route of administration: intravenous use” NCT03464227 ↗ |
| Target | MAPT | “Microtubule-associated protein tau inhibitor” CHEMBL4594612 ↗ |